VIVS (VivoSim Labs) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VIVS VivoSim Labs Inc VIVS
28 GF Score
Price $0.29
GF Value $1.21
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is VivoSim Labs Net Loan?

Net Loan only applies to banks and insurance companies.

VIVS
28GF Score
VivoSim Labs Inc VIVS
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VivoSim Labs (VIVS) Overvalued in 2026?

Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued. The current stock price of $0.29 is trading 76% below its estimated GF Value™ of $1.21. GuruFocus considers VivoSim Labs to be Possible Value Trap.

Key valuation signals for VIVS:

  • Net Loan:
  • GF Value™: $1.21 vs. price of $0.29 (76% below fair value)
  • GF Score™: 28/100 with 6 warning signs

No single metric tells the full story. See the VIVS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


VivoSim Labs Business Description

Address 11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
28GF Score

Get the complete analysis for VIVS

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.29
Price
$1.21
GF Value